Precigen (PGEN) Trading Performance and Board Update
Market Activity
- Price movement: Precigen shares increased by 4.23 % during a 24‑hour period that ended at 09:32 PM Central Europe on Tuesday, 20 October 2026.
- Current price: USD 6.86 on major exchanges.
- Shares outstanding: 358.7 million.
- Market capitalization: USD 2.3 billion.
- Volume (last 24 h): USD 27.6 million.
- Month‑end change: -13.51 % from the previous month.
- 200‑day simple moving average: USD 5.18.
- 52‑week range: Highest price USD 8.98 (30 September 2026); lowest price USD 3.04 (25 March 2026).
Corporate News
Precigen Inc., formerly known as Intrexon, announced that Geno Germano will join the company’s board of directors. Germano has more than 30 years of experience in biopharmaceutical development and commercialization, with prior senior leadership positions at Pfizer, Wyeth, and Johnson & Johnson. He previously served as president of Intrexon, the company that rebranded as Precigen. The addition of Germano is intended to strengthen Precigen’s governance and support ongoing research initiatives. No financial or operational changes were disclosed.
Related Stock Movements (Last 24 h)
| Ticker | Price Change | Current Price (USD) | Market Cap (USD bn) | P/E Ratio |
|---|---|---|---|---|
| MGEE | –1.33 % | 72.22 | 2.7 | 17.73 |
| DXPE | +1.82 % | 170.92 | 2.7 | 31 |
| MGRC | –0.65 % | 112.03 | 2.7 | 18.16 |
| ELVN | +3.7 % | 41.26 | 2.7 | – |
| AVAH | +0.81 % | 12.74 | 2.7 | 10.02 |
Enliven Therapeutics (ELVN) Additional Note
Enliven Therapeutics reported a Rule 144 filing for a block sale of common shares through a pre‑arranged 10b5‑1 plan. The transaction involves a director. The company also received a revised analyst outlook from HC Wainwright, which raised the target price while maintaining a bullish rating. Analyst coverage varies; some firms view the oncology pipeline positively, while others issue cautious recommendations. Institutional investors continue to hold significant positions, and the company focuses on developing small‑molecule treatments for cancers such as chronic myeloid leukemia and HER2‑driven cancers.
About Precigen
Precigen, Inc. is a biopharmaceutical company that develops gene and cell therapies for immuno‑oncology, autoimmune disorders, and infections. The company operates globally, with its headquarters in Germantown, United States. Its mission is to advance healthcare by providing innovative therapeutic solutions.
